High-Dose Naxitamab (Humanized-3F8) Plus Stepped-up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor for Consolidating ≥ 2nd Complete Remission of High-Risk Neuroblastoma

被引：0
|
作者：
Kushner, B. [1 ]
Modak, S. [1 ]
Basu, E. [1 ]
Roberts, S. [1 ]
Mauguen, A. [1 ]
Cheung, N. K. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Pediat, 1275 York Ave, New York, NY 10021 USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V349 SIOP1
引用
收藏
页码：S333 / S333
页数：1
相关论文
共 40 条
  • [31] RECOMBINANT HUMAN INTERLEUKIN-3 AND RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ADMINISTERED INVIVO AFTER HIGH-DOSE CYCLOPHOSPHAMIDE CANCER-CHEMOTHERAPY - EFFECT ON HEMATOPOIESIS AND MICROENVIRONMENT IN HUMAN BONE-MARROW
    ORAZI, A
    CATTORETTI, G
    SCHIRO, R
    SIENA, S
    BREGNI, M
    DINICOLA, M
    GIANNI, AM
    BLOOD, 1992, 79 (10) : 2610 - 2619
  • [32] Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.
    Lerman, Benjamin
    Li, Yimei
    Granger, Meaghan
    Cash, Thomas
    Sadanand, Arhanti
    Somers, Katherine
    Ranavaya, Aeesha
    Choe, Michelle
    Foster, Jennifer
    Morgenstern, Daniel A.
    Rafael, Margarida Simao
    Streby, Keri A.
    Zeno, Rachel
    Mody, Rajen
    Yazdani, Sahr
    Desai, Ami Vijay
    Macy, Margaret E.
    Shusterman, Suzanne
    Federico, Sara Michele
    Bagatell, Rochelle
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells
    Talleur, Aimee C.
    Triplett, Brandon M.
    Federico, Sara
    Mamcarz, Ewelina
    Janssen, William
    Wu, Jianrong
    Shook, David
    Leung, Wing
    Furman, Wayne L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (11) : 1910 - 1917
  • [34] Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
    Miller, LL
    Korn, EL
    Stevens, DS
    Janik, JE
    Gause, BL
    Kopp, WC
    Holmlund, JT
    Curti, BD
    Sznol, M
    Smith, JW
    Urba, WJ
    Donegan, SE
    Watson, TM
    Longo, DL
    BLOOD, 1999, 93 (10) : 3250 - 3258
  • [35] GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INTERLEUKIN-3 FUSION PROTEIN (PIXY-321) ENHANCES HIGH-DOSE ARA-C-INDUCED PROGRAMMED CELL-DEATH OR APOPTOSIS IN HUMAN MYELOID-LEUKEMIA CELLS
    BHALLA, K
    TANG, C
    IBRADO, AM
    GRANT, S
    TOURKINA, E
    HOLLADAY, C
    HUGHES, M
    MAHONEY, ME
    HUANG, Y
    BLOOD, 1992, 80 (11) : 2883 - 2890
  • [36] Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b and Granulocyte-Macrophage Colony-Stimulating Factor
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Jones, Dan
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Koller, Charles
    Hiteshew, Jody
    Shan, Jenny
    O'Brien, Susan
    Kantarjian, Hagop
    CANCER, 2011, 117 (03) : 572 - 580
  • [37] Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
    Le Cesne, A
    Judson, I
    Crowther, D
    Rodenhuis, S
    Keizer, HJ
    Van Hoesel, Q
    Blay, JY
    Frisch, J
    Van Glabbeke, M
    Hermans, C
    Van Oosterom, A
    Tursz, T
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) : 2676 - 2684
  • [38] TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) BEFORE AND DURING CONTINUOUS-INFUSION HIGH-DOSE ARA-C PLUS DAUNORUBICIN - COMPARISON TO PATIENTS TREATED WITHOUT GM-CSF
    ESTEY, E
    THALL, PF
    KANTARJIAN, H
    OBRIEN, S
    KOLLER, CA
    BERAN, M
    GUTTERMAN, J
    DEISSEROTH, A
    KEATING, M
    BLOOD, 1992, 79 (09) : 2246 - 2255
  • [39] Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma
    Hill, Colin S.
    Parkinson, Rose
    Jaffee, Elizabeth M.
    Sugar, Elizabeth
    Zheng, Lei
    Onners, Beth
    Weiss, Matthew J.
    Wolfgang, Christopher L.
    Cameron, John L.
    Pawlik, Timothy M.
    Rosati, Lauren
    Le, Dung T.
    Hacker-Prietz, Amy
    Lutz, Eric R.
    Schulick, Richard
    Narang, Amol K.
    Laheru, Daniel A.
    Herman, Joseph M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (04): : 930 - 941
  • [40] A PHASE-I TRIAL OF INTERLEUKIN-3 (IL-3) PRE-BONE MARROW HARVEST WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) POST-STEM CELL INFUSION IN PATIENTS WITH SOLID TUMORS RECEIVING HIGH-DOSE COMBINATION CHEMOTHERAPY
    SOSMAN, JA
    STIFF, PJ
    BAYER, RA
    PELISKA, J
    PEACE, DJ
    LOUTFI, S
    STOCK, W
    OLDENBURG, D
    UNVERZAGT, K
    BENDER, J
    FISHER, SG
    WEBER, L
    RAD, N
    KINCH, L
    BONE MARROW TRANSPLANTATION, 1995, 16 (05) : 655 - 661
1234